Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer

201540 citationsJournal Articlegreen Open Access

Authors

Kei Muro · Aichi Cancer Center

Sang Cheul Oh · Korea University

Yasuhiro Shimada · Tokyo National Hospital

Moon‐Hyoung Lee · Seoul National University Bundang Hospital

Chia‐Jui Yen · National Cheng Kung University

Yee Chao · Taipei Veterans General Hospital

Y. Choi ·

Abstract

Ramucirumab plus paclitaxel significantly improves progression-free survival and response rate, with prolonged median overall survival and an acceptable safety profile in East Asians with advanced gastric cancer.

Topics & Keywords

Gastric Cancer Management and Outcomes Colorectal Cancer Treatments and Studies Helicobacter pylori-related gastroenterology studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Gastroenterology and Hepatology

Volume 31, Issue 3, pp. 581-589

DOI: 10.1111/jgh.13153

Field-Weighted Citation Impact: 3.74